Calidi Biotherapeutics (CLDI) Income Statement (2021 - 2026)
Income Statement report data from Jun 30, 2021 to Mar 31, 2026 for Calidi Biotherapeutics (CLDI).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Sep 30, 2021 | Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||||||||
Total Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 50K | - | - | - | - | - |
Operating Expenses | |||||||||||||||||||
Research And Development | 2.59M (+9.75%) | 2.36M (0.00%) | 2.36M (-8.88%) | 2.59M (+7.02%) | 2.42M (+32.97%) | 1.82M (-15.35%) | 2.15M (-0.92%) | 2.17M (-20.80%) | 2.74M (-30.81%) | 3.96M (+21.85%) | 3.25M (+2.20%) | 3.18M (+21.37%) | 2.62M (-50.66%) | 5.31M (+172.31%) | 1.95M | - | - | - | - |
Selling General And Administrative | 1.60M (-24.17%) | 2.11M (-21.56%) | 2.69M (-12.38%) | 3.07M (+16.29%) | 2.64M (+19.46%) | 2.21M (-28.01%) | 3.07M (-14.96%) | 3.61M (-9.98%) | 4.01M (-31.57%) | 5.86M (+47.61%) | 3.97M (+18.15%) | 3.36M (+20.43%) | 2.79M (-74.31%) | 11M (+115.48%) | 5.04M | - | - | - | - |
Operating Expenses | 4.19M (-6.26%) | 4.47M (-11.49%) | 5.05M (-10.78%) | 5.66M (+11.86%) | 5.06M (+25.56%) | 4.03M (-22.94%) | 5.23M (-9.36%) | 5.77M (-14.52%) | 6.75M (-31.26%) | 9.82M (+36.01%) | 7.22M (+10.40%) | 6.54M (+20.89%) | 5.41M (-64.64%) | 15M (+118.88%) | 6.99M (+1841.67%) | 360K (-32.08%) | 530K (-51.38%) | 1.09M (+1262.50%) | 80K |
Depreciation And Amortization | 430K (-65.87%) | 1.26M | - | - | 390K (-68.29%) | 1.23M (+1130.00%) | 100K (0.00%) | 100K (0.00%) | 100K (0.00%) | 100K (0.00%) | 100K (0.00%) | 100K (+11.11%) | 90K (-43.75%) | 160K (+60.00%) | 100K | - | - | - | - |
Operating Income | |||||||||||||||||||
Operating Income | -4.19M (-6.26%) | -4.47M (-11.49%) | -5.05M (-10.78%) | -5.66M (+11.86%) | -5.06M (+25.56%) | -4.03M (-22.94%) | -5.23M (-9.36%) | -5.77M (-14.52%) | -6.75M (-31.26%) | -9.82M (+36.01%) | -7.22M (+10.40%) | -6.54M (+20.89%) | -5.41M (-64.52%) | -15.25M (+118.17%) | -6.99M (+1841.67%) | -360.00K (-32.08%) | -530.00K (-51.38%) | -1.09M (+1262.50%) | -80.00K |
Ebit | -4.19M (-6.26%) | -4.47M (-11.49%) | -5.05M (-10.78%) | -5.66M (+11.86%) | -5.06M (+25.56%) | -4.03M (-22.94%) | -5.23M (-9.36%) | -5.77M (-14.52%) | -6.75M (-31.26%) | -9.82M (+36.01%) | -7.22M (+10.40%) | -6.54M (+20.89%) | -5.41M (-64.52%) | -15.25M (+118.17%) | -6.99M (+1841.67%) | -360.00K (-32.08%) | -530.00K (-51.38%) | -1.09M (+1262.50%) | -80.00K |
EBITDA | -3.76M (+19.75%) | -3.14M (-38.55%) | -5.11M (-9.88%) | -5.67M (+21.41%) | -4.67M (+67.38%) | -2.79M (-45.61%) | -5.13M (-9.52%) | -5.67M (-14.74%) | -6.65M (-31.58%) | -9.72M (+36.52%) | -7.12M (+10.56%) | -6.44M (+21.05%) | -5.32M (+44.96%) | -3.67M (-46.73%) | -6.89M (+50.44%) | -4.58M (-40.83%) | -7.74M (+843.90%) | -820.00K (+925.00%) | -80.00K |
Other Income / Expenses | |||||||||||||||||||
Interest Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.27M | 1.09M (+581.25%) | 160K (+700.00%) | 20K | - | - |
Interest Expense | 20K | -70.00K | 30K (-25.00%) | 40K (-60.00%) | 100K | - | 200K (0.00%) | 200K (-33.33%) | 300K (0.00%) | 300K (0.00%) | 300K (0.00%) | 300K (+50.00%) | 200K (+17.65%) | 170K (+466.67%) | 30K | - | - | - | - |
Net Interest Income | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.27M | 1.09M (+581.25%) | 160K (+700.00%) | 20K | - | - |
Other Non Operating Income | 70K (-30.00%) | 100K (+400.00%) | 20K | -20.00K (+100.00%) | -10.00K | 10K (0.00%) | 10K (0.00%) | 10K | -20.00K (-60.00%) | -50.00K (+400.00%) | -10.00K (-50.00%) | -20.00K | - | - | - | 4.52M (+127.14%) | 1.99M (+637.04%) | 270K | - |
Net Income | |||||||||||||||||||
Income Before Tax | -4.10M (+0.99%) | -4.06M (-21.47%) | -5.17M (-10.24%) | -5.76M (+13.83%) | -5.06M (+22.22%) | -4.14M (-18.34%) | -5.07M (-11.98%) | -5.76M (-20.22%) | -7.22M (-12.27%) | -8.23M (+309.45%) | -2.01M (-83.92%) | -12.50M (+93.50%) | -6.46M (-74.85%) | -25.69M (+380.19%) | -5.35M | 4.16M (+184.93%) | 1.46M | -820.00K | - |
Income Tax Expense | - | - | 10K | - | - | - | - | 10K | - | - | 10K | - | - | 10K | - | - | - | - | - |
Net Income From Continuing Operations | -4.11M (+1.23%) | -4.06M (-21.17%) | -5.15M (-9.81%) | -5.71M (+14.43%) | -4.99M (+21.71%) | -4.10M (-18.81%) | -5.05M (-12.48%) | -5.77M (-20.08%) | -7.22M (-12.27%) | -8.23M (+307.43%) | -2.02M (-83.84%) | -12.50M (+93.50%) | -6.46M (-16.75%) | -7.76M (+45.05%) | -5.35M (+16.81%) | -4.58M (-40.83%) | -7.74M (+843.90%) | -820.00K (+925.00%) | -80.00K |
Net Income | -4.11M (+1.23%) | -4.06M (-21.17%) | -5.15M (-9.81%) | -5.71M (+14.43%) | -4.99M (+21.71%) | -4.10M (-18.81%) | -5.05M (-12.48%) | -5.77M (-20.08%) | -7.22M (-12.27%) | -8.23M (+307.43%) | -2.02M (-83.84%) | -12.50M (+93.50%) | -6.46M (-16.75%) | -7.76M (+45.05%) | -5.35M (+16.81%) | -4.58M (-40.83%) | -7.74M (+843.90%) | -820.00K (+925.00%) | -80.00K |
Comprehensive Income Net Of Tax | -4.12M (-79.29%) | -19.89M (+286.21%) | -5.15M (-9.65%) | -5.70M (+14.46%) | -4.98M (-77.49%) | -22.12M (+333.73%) | -5.10M (-12.07%) | -5.80M (-19.11%) | -7.17M (-75.49%) | -29.25M (+1355.22%) | -2.01M (-83.93%) | -12.51M (+93.65%) | -6.46M (-74.61%) | -25.44M (+373.74%) | -5.37M | - | - | - | - |